Oramed Pharmaceuticals Inc.Find Ratings Reports
ORAMED PHARMACEUTICALS INC's gross profit margin for the first quarter of its fiscal year 2021 has significantly decreased when compared to the same period a year ago. While net income decreased, sales have remained unchanged. ORAMED PHARMACEUTICALS INC is extremely liquid. Currently, the Quick Ratio is 5.98 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has decreased from the same period last year, indicating deteriorating cash flow.
At the same time, stockholders' equity ("net worth") has greatly increased by 64.40% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q1 FY21||Q1 FY20|
|Net Sales ($mil)||0.67||0.67|
|Net Income ($mil)||-5.57||-2.54|
|Balance Sheet||Q1 FY21||Q1 FY20|
|Cash & Equiv. ($mil)||34.35||30.13|
|Total Assets ($mil)||40.97||31.14|
|Total Debt ($mil)||0.64||0.11|
|Profitability||Q1 FY21||Q1 FY20|
|Gross Profit Margin||-864.24||-360.39|
|Return on Assets||-35.48||-40.44|
|Return on Equity||-51.53||-73.4|
|Debt||Q1 FY21||Q1 FY20|
|Share Data||Q1 FY21||Q1 FY20|
|Shares outstanding (mil)||23.81||17.4|
|Div / share||0.0||0.0|
|Book value / share||1.18||0.99|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||572859.0||133575.0|
SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. To use another comparison, its price-to-book ratio of 3.87 indicates valuation on par with the S&P 500 average of 4.08 and a significant discount versus the subsector average of 9.87. The price-to-sales ratio is well above both the S&P 500 average and the subsector average, indicating a premium. The valuation analysis reveals that, ORAMED PHARMACEUTICALS INC seems to be trading at a premium to investment alternatives.
|ORMP NM||Peers 29.28||ORMP NM||Peers 34.71|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
ORMP's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
ORMP's P/CF is negative making the measure meaningless.
|ORMP NM||Peers 18.08||ORMP NA||Peers 0.45|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
ORMP's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|ORMP 3.87||Peers 9.87||ORMP 8.34||Peers 29.97|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
ORMP is trading at a significant discount to its peers.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, ORMP is expected to significantly trail its peers on the basis of its earnings growth rate.
|ORMP 40.24||Peers 33.58||ORMP 0.25||Peers 29.01|
Premium. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
ORMP is trading at a premium to its subsector on this measurement.
Lower. A sales growth rate that trails the subsector implies that a company is losing market share.
ORMP significantly trails its peers on the basis of sales growth.